Resumen

TORRES-GONZALEZ, July Vianneth et al. Pulmonary Fibrosis in SARS-CoV2 Infection. What we Know? What we could Expect?. Univ. Med. [online]. 2020, vol.61, n.4, pp.166-175.  Epub 30-Sep-2020. ISSN 0041-9095.  https://doi.org/10.11144/javeriana.umed61-4.fibr.

SARS-CoV-2 infection has brought great challenges for health personnel during 2020. Learn about the behavior of the virus, the pathophysiology of the disease, lung involvement and its progression to respiratory distress syndrome (ARDS), in addition to pharmacological interventions and mortality have represented a scientific challenge in specialized care centers. However, despite the progress that has been made in acute infection, little is known about the potential sequelae after mild, moderate, or severe SARS-CoV-2 infection, including the possible fibrosing involvement of the lung parenchyma, which according to the previous experience on infections by other coronaviruses (SARS and MERS) and other causes of ARDS, it can be one of the most severe complications and with the greatest impact on the quality of life and functionality of people, once the infection is over. In this document, we present a review of the available evidence on the development of fibrosing-type interstitial lung disease associated with SARS-CoV-2 infection, possible pathophysiological mechanisms, imaging findings, and the management plan proposed so far, especially in terms of comprehensive rehabilitation of these patients.

Palabras clave : pulmonary fibrosis; SARS-CoV-2; COVID 19; pulmonary rehabilitation.

        · resumen en Español     · texto en Español     · Español ( pdf )